Lab2Market: A novel strategy towards the computational development of peptide 'disruptors' to be used as molecular probes or therapeutic molecules.

Lab2Market：一种新的策略，旨在计算开发用作分子探针或治疗分子的肽“干扰物”。

• 批准号: 571233-2022
• 负责人: Biggar, Kyle
• 金额: $ 1.46万
• 依托单位: Carleton University
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=729087
• 关键词: Lab2Market; novel; strategy; towards; computational

Through the Lab2Market partner program, we are proposing to bring to market software that enables rapid screening and development of novel peptide therapeutics. Indeed, the front runners in the game of drug delivery include small molecule and large molecule drugs, but there is another class that lands right in between; peptides. Since the introduction of insulin peptides for the treatment of diabetes in 1921, more than 100 peptide drugs have reached the market for a number of diseases, including cancer, multiple sclerosis, HIV infection, and chronic pain (10 peptides since 2017). New market growth into peptide therapeutics has resulted in >150 peptides in clinical development and another >600 peptides undergoing preclinical studies. The market is growing faster than any other therapeutics and is estimated at >$40 billion per year, with a double approval rate compared to small molecule drugs. To directly address challenges in generating new peptides to permit market growth, we have developed TIPS (The In silico Peptide Synthesizer), a computational method for developing peptide-based inhibitors. This computational pipeline promises to decrease the time and research screening costs to efficiently design target-specific inhibitors. Our objective is to carry out a Market Assessment to determine appropriate strategies to license our software to key industry partners.

通过LAB2Market合作伙伴计划，我们提议将新型肽治疗剂的快速筛查和开发带入市场软件。的确，药物输送游戏中的前跑者包括小分子和大分子药物，但是还有另一个阶层介于两者之间。肽。 自1921年引入胰岛素肽治疗糖尿病的胰岛素以来，有100多种肽药物已经进入了多种疾病的市场，包括癌症，多发性硬化症，HIV感染和慢性疼痛（自2017年以来10种肽）。肽疗法的新市场增长导致临床发育中> 150种肽，另一种> 600肽正在进行临床前研究。该市场的增长速度高于任何其他治疗剂，估计每年400亿美元，与小分子药物相比，批准率具有双重批准率。为了直接应对生成新肽以允许市场增长的挑战，我们开发了一种尖端（In In In Silico肽合成器），这是一种用于开发基于肽的抑制剂的计算方法。该计算管道有望减少时间和研究筛查成本，以有效设计目标特异性抑制剂。我们的目标是进行市场评估，以确定适当的策略将我们的软件许可给关键行业合作伙伴。